The rising cost of cancer care in the United States—particularly the direct financial burden experienced by patients through out-of-pocket costs (OOPCs)—has been thoroughly documented in recent literature. This issue is especially acute among Medicare beneficiaries. Individuals with Medicare coverage who receive a new cancer diagnosis frequently incur thousands of dollars in annual medical expenses. Among those without supplemental Medicare insurance, OOPCs may account for more than half of their yearly household income. Although the Affordable Care Act has provided some financial relief—particularly through modifications to Medicare Part D—substantial out-of-pocket expenditures persist, particularly for inpatient hospital admissions and prescription drug costs. These financial burdens, often referred to as “financial toxicity,” have been consistently linked to reduced medication adherence. Given that the majority of cancer patients are aged 65 or older and therefore Medicare-eligible, research has primarily focused on this group. However, with the increasing incidence of cancer among younger adults under the age of 65—those not yet eligible for Medicare—there is a growing need to investigate OOPCs within privately insured populations better to understand the financial implications for this emerging demographic.

Estimating OOPCs associated with specific cancer types in privately insured adults has proven challenging for several reasons. Traditional survey-based datasets that examine healthcare expenditures—such as the Medical Expenditure Panel Survey (MEPS)—lack sufficient sample sizes to permit stratification by both cancer site and stage. Furthermore, these surveys are prone to systematically underestimating actual healthcare costs. In contrast, administrative claims databases, such as MarketScan and the OptumLabs Data Warehouse, offer larger sample sizes and more reliable cost data. However, these datasets often fall short in terms of clinical detail. Staging information, when present, is inconsistently reported and lacks the methodological rigour found in population-based cancer registries, such as the Surveillance, Epidemiology, and End Results (SEER) programme, which relies on validated medical record reviews. Therefore, to effectively identify patient subgroups at elevated risk for high OOPCs, a comprehensive linkage between detailed clinical cancer data and insurance claims is essential.

While linkages between Medicare claims and SEER data have already facilitated such analyses within publicly insured populations, similar integrated datasets for privately insured individuals have remained elusive. This absence of high-quality linked data has hindered efforts to examine the financial burden of cancer in younger, working-age adults who are enrolled in private insurance plans.

To address this critical gap, a recent study leveraged a novel dataset combining SEER registry data with claims from the OptumLabs Data Warehouse, representing the largest private health insurer in the United States. This integrated data resource enables accurate identification of key cancer characteristics, including the anatomical site and stage at diagnosis, alongside granular cost data specific to each patient’s insurance policy. Importantly, this linkage permits the isolation of costs directly attributable to the cancer diagnosis from a patient’s baseline healthcare utilisation and spending.

Using this rich dataset, researchers employed a difference-in-differences (DiD) analytical design to compare changes in OOPCs for individuals diagnosed with cancer before and after their diagnosis, relative to a matched cohort of individuals without cancer. This methodological approach helps mitigate potential confounding by accounting for time-related changes in healthcare spending unrelated to cancer status. The use of DiD enables a more robust estimation of the financial impact of cancer diagnosis and treatment within a privately insured, working-age population—a segment of the public whose insurance coverage is often more fragmented and whose financial vulnerability may differ significantly from older, Medicare-covered individuals.

The study contributes novel evidence to the growing literature on cancer-related financial toxicity by providing precise, empirically grounded estimates of OOPCs among privately insured adults. These findings have significant implications for healthcare providers, insurers, and policymakers seeking to alleviate the financial burden of cancer care and enhance patient outcomes. Moreover, the study underscores the broader importance of integrated health data infrastructures that bridge clinical and administrative domains, thereby enabling more nuanced and equitable health policy planning across all segments of the insured population—not just those served by public insurance programmes.

More information: Liam Rose et al, Estimated Out-of-Pocket Costs for Patients With Common Cancers and Private Insurance, JAMA Network Open. DOI: 10.1001/jamanetworkopen.2025.21575

Journal information: JAMA Network Open Provided by JAMA Network